Healthcare ETF flows could bolster Dexcom stock forecast 2025, as DXCM remains a core holding in growth-focused portfolios seeking exposure to medtech innovation. Sayer also shared an update on Stelo, Dexcom’s first over-the-counter CGM launched in the U.S. in August. The device is targeted at people who don’t take insulin, in particular people who have Type 2 diabetes or prediabetes. However, adjusted earnings fell 10% year-over-year to $0.45 per share, missing the consensus estimate of $0.50. The decline was primarily due to operational and cost challenges faced by the company, which led to a fall in both gross and operating margins. Despite these challenges, DexCom's management reaffirmed its fiscal year 2025 forecast, anticipating revenue growth of 14% with a non-GAAP operating margin goal of around 21%. Analysts tracking Dexcom stock forecast 2025 expect strong performance in North America and EU markets, aided by regulatory approvals and insurance coverage expansion for glucose monitoring solutions.
